Pharmafile Logo

tenofovir disproxil

- PMLiVE

Sanofi backs vaccines unit with €350m Canadian facility

The new plant will make paediatric and booster vaccines

- PMLiVE

Novo Nordisk appoints new general manager

Pinder Sahota also becomes the corporate vice president, UK

Segmentation, evolved

My research into the evolution of the life science industry reveals broad, sweeping trends, as I wrote about in previous PME articles such as “Selection Pressures” and “Explosive Evolution”. But...

- PMLiVE

Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

The candidate is expected to start a phase II trial in the coming months

Sanofi reception

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

Dupixent is still too expensive despite discount, says the UK’s cost effectiveness body

Sanofi reception

Sanofi’s PD-1 inhibitor starts EU review for skin cancer

Cemiplimab could be the first PD-1-targeting drug approved for CSCC

- PMLiVE

ViiV’s two-drug HIV combo backed by CHMP

The committee also backs two biosimilar medicines

- PMLiVE

Novo Nordisk’s semaglutide obesity trial hits the mark

The injection helped adults lose up to 13.8% of their body weight in a year

Sanofi reception

Sanofi, Regeneron offer price cut for cholesterol drug Praluent

Amgen’s Repatha also struggled to secure reimbursement at its launch price point

Sanofi reception

Sanofi taps Evotec for new anti-infectives drive

The duo will set up the initiative at Sanofi’s R&D unit in France

Gilead Sciences

Gilead says switching studies back new HIV therapy Biktarvy

Patients who switched from rival Triumeq could maintain viral suppression over the trial period

Sanofi ponders which African health tech start-ups to bring to Paris

It's on the look out for those working in non-communicable diseases, telemedicine and HCP education

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links